Exelixis Stock: A Biotech Winner's Valuation Puzzle After Years of Stellar Gains
Exelixis shares have delivered impressive multi-year returns, but recent price weakness has investors questioning if the rally has run its course. A deep dive into valuation models suggests the stock may still be significantly undervalued, presenting a potential opportunity amidst market uncertainty.